News and Trends 12 Jan 2023 Ajinomoto and Exelixis to discover and develop novel ADCs to treat cancer Ajinomoto Co., Inc. has signed a license agreement with Exelixis, Inc. to incorporate AJICAP, Ajinomoto Co.’s proprietary site-specific bioconjugation and linker technologies, in the development of some of Exelixis’ antibody-drug conjugate (ADC) programs. Exelixis is an oncology-focused biotechnology company looking to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Utilizing its […] January 12, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Renexxion goes to FDA with cystic fibrosis drug Renexxion Ireland Limited has opened an investigational new drug (IND) application with the U.S Food and Drug Administration (FDA) for naronapride for the treatment of GI motility disorders in patients with cystic fibrosis (CF). This is a first step towards conducting clinical trials of the drug candidate in CF patients. Naronapride, post approval, could be […] January 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 New nanotransporter delivers drugs inside cells A new study by the University of Barcelona in Spain has analyzed the viability of a new nanomolecule that can be used as a nanotransporter to deliver drugs. The results, published in the journal Colloids and Surfaces B: Biointerfaces, show that liposomes designed by researchers are able to transport and deliver an anticancer drug that […] January 11, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 AstraZeneca’s Airsupra gets US approval as new rescue treatment for asthma Avillion LLP says the US Food and Drug Administration (FDA) has approved AstraZeneca’s Airsupra for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older. Airsupra, (albuterol/budesonide, formerly known as PT027) is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication […] January 11, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Five key trends shaping life sciences in 2023 By Kevin Wayer, president – government, education, infrastructure and life sciences industries, JLL, and Travis McCready, head of life sciences, industries Americas, JLL After an unprecedented period of growth during the pandemic, life sciences activity normalized in 2022. The life sciences industry has not been immune to the macroeconomic challenges plaguing the global economy, but […] January 11, 2023 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 AbbVie bets on Anima mRNA modulators to tackle cancer AbbVie and Anima Biotech have announced a collaboration to discover and develop mRNA biology modulators for three targets in oncology and immunology. Anima Biotech will use its mRNA Lightning platform to discover novel mRNA biology modulators against the collaboration targets, providing AbbVie exclusive rights to license and further develop and commercialize the programs. “This collaboration […] January 11, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 2023 life sciences industry trends: adopting a digital-first mindset By Pat Jenakanandhini, chief product officer, ArisGlobal With the new year here, life science organizations have reached technology crossroads in choosing whether to embrace a digital-first mindset and adopt innovative digital technologies or hold fast to legacy processes. Digital transformation has driven newer technologies designed to improve efficiency, patient care and workflows. Those who choose […] January 11, 2023 - 4 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 What the new year holds for clinical research Catherine Gregor is the chief clinical trial officer at Florence Healthcare. The company’s clinical trial software is used in more than 12,000 research sites in 45 countries for management of documents, data, and workflows. We asked Gregor about the clinical trial technology landscape in 2023. Why is remote clinical research connectivity so important? Remote connectivity […] January 11, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Silo Pharma looks into the 2023 psychedelics crystal ball Labiotech had the opportunity to ask James Kuo, vice president of R&D at Silo Pharma Inc., about his predictions for the field of psychedelic research in 2023. Silo Pharma is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare […] January 11, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 Clinical trends for 2023 By Richard Staines, account director, Optimum Strategic Communications Few would deny that the decade has had a turbulent start, but after the tragedies of the COVID-19 pandemic and the Ukraine war, there’s hope that 2023 will see a new wave of clinical research. Exciting new technologies such as gene editing, gene therapy and a next […] January 11, 2023 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 What’s in store for biotech in 2023? Perhaps 2022 will best be remembered in the life science industry for the return of many of the face-to-face events that fell by the wayside during the COVID-19 pandemic. It might have been a mixed year for biotech companies, but 2023 is a new year, with new challenges, but also new opportunities. So what do […] January 11, 2023 - 14 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jan 2023 2023: A pivotal time for medicine as it enters a new ‘personalized’ era By Hakim Yadi, co-founder and CEO of Closed Loop Medicine The traditional healthcare delivery model is designed to cater to the masses, rather than the individual. Administering treatments based on the overall safety and efficacy demonstrated in large-scale clinical trials, and not taking into consideration individual responses to such treatments, is resulting in poorer outcomes […] January 11, 2023 - 5 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email